Results 11 to 20 of about 196,130 (124)
To evaluate short‐term changes in tricuspid regurgitation (TR) after transcatheter edge‐to‐edge mitral valve repair (M‐TEER) in secondary mitral regurgitation (SMR), their predictors and impact on mortality.
M. Adamo+41 more
semanticscholar +1 more source
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.
BACKGROUND Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in ...
J. Gammie+33 more
semanticscholar +1 more source
The Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) was conceived in order to assess the safety and efficacy of MitraClip therapy in Italy. The aim of this study was to assess
F. Bedogni+21 more
semanticscholar +1 more source
Mild to moderate functional mitral regurgitation (MR) is common in patients with heart failure and preserved ejection fraction (HFpEF) where it is usually considered as an innocent bystander. We hypothesized that MR in HFpEF reflects greater left atrial (
M. Tamargo+7 more
semanticscholar +1 more source
Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation
BACKGROUND In patients who have chronic heart failure with reduced left ventricular ejection fraction, severe secondary mitral‐valve regurgitation is associated with a poor prognosis. Whether percutaneous mitral‐valve repair improves clinical outcomes in
J. Obadia+29 more
semanticscholar +1 more source
MitraClip therapy for the treatment of functional mitral regurgitation (FMR) is an increasingly used intervention for high‐risk surgical patients. The aim of this observational study was to assess the impact of residual mitral regurgitation (rMR) at ...
D. Reichart+10 more
semanticscholar +1 more source
The contradictory findings of recent prospective randomized controlled trials assessing the impact of percutaneous edge-to-edge repair in patients with functional or secondary mitral regurgitation have triggered a lively discussion about an “integrated ...
A. Hagendorff+5 more
semanticscholar +1 more source
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Background: The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was that sacubitril/valsartan would be superior to valsartan
D. Kang+9 more
semanticscholar +1 more source
To summary the impact of off-pump coronary artery bypass grafting (CABG) only on patients with moderate ischemic mitral regurgitation and survival. We retrospectively analyzed 109 patients with coronary artery disease (CAD) complicated by moderate mitral
Weitie Wang+7 more
semanticscholar +1 more source
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.
BACKGROUND In a randomized trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemic mitral regurgitation, we found no significant difference in the left ventricular end-systolic volume index (LVESVI), survival ...
D. Goldstein+30 more
semanticscholar +1 more source